Nanofiltration of plasma-derived biopharmaceutical products

Haemophilia

Volumn 9, Issue 1, 2003, Pages 24-37

  Burnouf, Thierry ^a   Radosevich, M ^a  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

Author keywords

Nanofiltration; Plasma; Prions; Validation; Viral safety; Virus

Indexed keywords

ALPHA INTERFERON; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; FIBRINOGEN; HEMOGLOBIN; IMMUNOGLOBULIN G; PLASMA PROTEIN; PROTEINASE INHIBITOR; PROTHROMBIN COMPLEX; TRANSFERRIN; VON WILLEBRAND FACTOR;

DRUG CONTAMINATION; DRUG MANUFACTURE; HUMAN; INTERMETHOD COMPARISON; LICENCE; MEMBRANE FILTER; MICROFILTRATION; NANOFILTRATION; PRION; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION; VIRAL CONTAMINATION; VIRUS INACTIVATION;

EID: 0037276210     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00701.x     Document Type: Review

References (96)

1. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products; specific preventative strategies. Blood Rev 2000; 14: 94-110.
2. Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol 1996; 93: 457-9.
3. Prowse C, Ludlam CA, Yap PL. Human parvovirus B 19 and blood products. Vox Sang 1997; 72: 1-10.
4. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-9.
5. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 247: 921-5.
6. Bruce ME, Will RG, Ironside JW et al. Transmission to mice indicates that new variant CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
7. van Reis R, Zydney A. Membrane separations in biotechnology. Curr Opin Biotechnol 2001; 12: 208-11.
8. Manabe SI, Kamata Y, Iijima H, Kamide K. Some morphological characteristics of porous polymeric membranes prepared by 'micro-phase' separation method. Polymer J 1987; 19: 391-404.
9. Sekiguchi S, Ito K, Kobayashi M et al. Possibility of hepatitis B virus (HBV) removal from human plasma using regenerated cellulose hollow fiber (BMM). Membrane 1989; 14: 253-61
10. Burnouf T, Burnouf-Radosevich M. Strategy of virus removal/inactivation of plasma-derived products: interest of nanofiltration as a new virus elimination method. In: Kobayashi T, Kitagawa Y, Okumura K, eds, Animal Cell Technology: Basic and Applied Aspects Vol. 6, Kluwer Academic Publishers, the Netherlands, 1994; 17-27.
11. Burnouf T. Value of virus filtration as a method for improving the safety of plasma products. Vox Sang 1996; 70: 235-6.
12. Hughes BA, Sheppard A, Young D. Evaluation of antiviral filters. Dev Biol Stand 1996; 88: 91-8.
13. Viresolve. Virus and Application Filtration Guide, 2002, Millipore.
14. OMEGA VR™ virus reduction membrane. Element Data Sheet F1, Pall Corporation, 1996.
15. Manabe S, Tsurumi T, Ishikawa G et al. Mechanism of human immunodeficiency virus (HIV) removal by regenerated cellulose hollow fiber (BMM). Membrane 1989; 14: 77-83.
16. Manabe SI, Kamata Y, Iijima H, Kamide K. Some morphological characteristics of porous polymeric membranes prepared by 'micro-phase' separation method. Polymer J 1987; 19: 391-404.
17. Manabe S. Removal of virus through novel membrane filtration method. Dev Biol Stand 1996; 88: 81-90.
18. Ide S, Development of new Planova® membrane - the Planova® 2ON filter. Planova® Workshop Japan, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration. Tokyo: Asahi Kasei Corporation, November 1, 2000.
19. Tsurumi T, Osawa N, Hitaka H et al. Structure of cuprammonium regenerated hollow fiber (BMM hollow fiber) for virus removal. Polymer J 1990; 22: 751-8.
20. Yamaguchi K, Hamamoto Y, Manabe SI, Yamamoto N. Microparticle removability of the regenerated cellulose hollow fiber (BMM): an electron microscopic evaluation. J Electron Microsc 1991; 40: 337-45.
21. Viresolve NFP filters. Data Sheet. Millipore 9/1/2001.
22. Viresolve NFR filters. Data Sheet. Millipore 12/99.
23. Graf EG, Jander E, West A, Pora H, Aranha-Creado H. Virus removal by filtration. Dev Biol Stand 1999; 99: 89-94.
24. Brandwein H, Aranha-Creado H. Membrane filtration for virus removal. Dev Biol Stand 2000; 102:157-63.
25. Oshima KH, Evans-Strickfaden TT, Highsmith AK. Comparison of filtration properties of hepatitis B virus, hepatitis C virus and simian virus 40 using a polyvinylidene fluoride membrane filter. Vox Sang 1998; 75: 181-8.
26. Validation Guide VG-DV20, Pall ULTIPOR VF Grade DV20 AB style virus removal filter cartridges. Pall BioPharmaceuticals, 2000.
27. Aranha-Creado H, Oshima K, Jafari S, Howard G, Brandwein H. Virus retention by Ultipor VF grade DV50 membrane filters. Pall STR 1543.
28. Aranha-Creado H, Oshima K, Jafari S, Howard G, Brandwein H. Virus retention by a hydrophilic triple-layer PVDF microporous membrane filter. PDA J Pharm Sc Technol 1997; 51: 119-24.
29. Burnouf T. Chromatographic removal of viruses from plasma derivatives. Dev Biol Stand 1993; 81: 199-209.
30. Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products. In: Horowitz B, Minor P, Morgenthaler JJ, Burnouf T, McIntosh R, Padilla A, Thorpe R. (drafting group), Geneva: WHO. BS/01/1941, 2002 (in press).
31. Peerlinck K, Arnout J, Di Giambattista M et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
32. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia patients in The Netherlands. Blood 1993; 81: 2180-6.
33. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T. Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994; 67: 132-8.
34. Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX:C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-32.
35. Goudemand J, Peynet J, Chambost H et al. A crossover pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb Haemost 1998; 80: 919-24.
36. Mannucci PM, Tradati F. Preliminary evaluation of a nanofiltered factor IX concentrate. Thromb Haemost 1995; 73: 737-8.
37. Yunoki M. Usefulness of Planova® filtration in virus inactivation/removal. Planova® Workshop Japan, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration. Tokyo: Asahi Kasei Corporation, November 1, 2000.
38. Feldman P, Roberts P. Virus-filtration of factor IX - an approach to process validation. Planova® Workshop, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology. Oslo: Asahi Chemical Industry Co. Ltd, June 27, 1998: 47-55.
39. Hoffer L, Schwinn H, Biesert L, Josic D. Improved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration. J Chromatogr B Biomed Appl 1995; 669: 187-96.
40. Johnston A, Macgregor A, Borovec S et al. Inactivation and clearance of viruses during the manufacture of high purity factor IX. Biologicals 2000; 28: 129-36.
41. Feldman F, Chandra S, Huang C. Improved safety from plasma derivatives: purification and viral elimination characteristics of mononine. Acta Haematol 1995; 94: 25-32.
42. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery. Haemophilia 1999; 5: 96-100.
43. Pejaudier L, Kichenin-Martin V, Boffa MC, Steinbuch M. Appraisal of the protein composition of prothrombin complex concentrates of different origins. Vox Sang 1987; 52: 1-9.
44. Romisch J, Groner A, Bernhardt D et al. Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality. Beitr Infusionsther Transfusionsmed 1996; 33: 220-4.
45. Nowak T, Groner A, Schuler E. Removal of viruses from a plasma intermediate by Planova® 35. Planova® Workshop, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology. Oslo: Asahi Chemical Industry Co. Ltd, June 27, 1998: 16-26.
46. Josic D, Hoffer L, Buchacher A et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res 2000; 100: 433-41.
47. Over J. Nanofiltration, the EPFA experience. Planova® Workshop, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology. Oslo: Asahi Chemical Industry Co. Ltd, June 27, 1998: 5-15.
48. Burnouf T. Chromatography in plasma fractionation: benefits and future trends review. J Chromatogr Biomed Appl 1995; 664: 3-15.
49. Burnouf T, Radosevich M. Affinity chromatography in the industrial purification of plasma proteins for therapeutic use.J Biochem Bioph Meth 2001; 49: 575-86.
50. Maeno H. Improvements of viral safety in plasma derivatives by introduction of Planova® filtration and its remaining problems. Planova® Workshop Japan, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration. Tokyo: Asahi Kasei Corporation, November 1, 2000: 21-37.
51. Takeda Y, Wakisaka A, Noguchi K et al. Receptor-mediated haemagglutination screening and reduction in the viral load of parvovirus B19 DNA in immunopurified factor VIII concentrate (Cross Eight®). Vox Sang 2001; 81: 266-8.
52. Chtourou S. FVIII SD-35-15, new safety standard for plasma-derived FVIII Planova® Workshop Japan, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration. Tokyo: Asahi Kasei Corporation, November 1, 2000: 91-114.
53. Burnouf T, Burnouf-Radosevich M, Huart JJ, Goudemand M. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang 1991; 60: 8-15.
54. Rothschild F, Alcalay M, Bertrand MA et al. Factor VIII SD-35-15: Preliminary Results of a Cross-Over Pharmacokinetic Study of SD and 35-15 nm Filtered Factor VIII Concentrate Compared to Reference Product (SD Factor VIII Concentrate)). XVII Congress of the International Society of Thrombosis and Haemostasis, August 1999. (Abstract)
55. Aubin JT, Defer C, Vidaud M, Maniez-Montreuil M, Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang 2000; 78: 7-12.
56. Burnouf-Radosevich M, Burnouf T. A therapeutic highly purified factor XI concentrate from human plasma. Transfusion 1992; 32: 861-7.
57. Burnouf-Radosevich M, Burnouf T. Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. Vox Sanguinis 1992; 62: 1-11.
58. Borel-Derlon A. vWF SD-35-DH: pharmacokinetic data and clinical efficacy. Plasma-Derived Medical Products and Haemostasis: Current Issues and Perspectives. 3eme Journees LFB, Brussels, 12-13th October 2000.
59. Yap PL, Williams PE. The safety of IVIG preparations. In: Yap PL, ed. Clinical Applications of Intravenous Immunoglobulin Therapy. Churchill Livingstone, UK, 1992:43-62.
60. Troccoli NM, McIver J, Losikoff A, Poiley J. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. Biologicals 1998; 26: 321-9.
61. Eibl J, Barrett N, Hammerle T, Dorner F. Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV. Biologicals 1996; 24: 285-7.
62. Dichtelmuller H, Rudnick D, Rinscheid V et al. Removal of viruses by Asahi 35 nm nanofiltration by IVIG. Planova® Workshop, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology. Oslo: Asahi Chemical Industry Co. Ltd, June 27, 1998: 27-37.
63. Suomela H. Virus removal filtration of factor IX concentrate and IV immunoglobulin by Planova® 15. Planova® Workshop, To Meet and Exchange Information on the Latest Developments in Virus Removal Technology. Oslo: Asahi Chemical Industry Co. Ltd, June 27, 1998: 38-46.
64. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. Safety profile of WinRho anti-D. Semin Hematol 1998; 35: 9-13.
65. Stucki M, Moudry R, Kempf C, Omar A, Schlegel A, Lerch PG. Characterisation of a chromatographically produced anti-D immunoglobulin product. J Chromatogr B Biomed Sci Appl 1997; 24: 241-8.
66. Price H. The use of Planova® 35 filters in the production of hyperimmune plasma product. Planova® Workshop USA'99. A Forum for Exchanging Information on the Latest Developments in Virus Removal Technology. Washington: Asahi Kasei Corporation, November 29, 1999: 21-33.
67. Maeno H. Improvements of viral safety in plasma derivatives by Planova filtration and its remaining problems. Planova® Workshop Japan, A Forum for Exchanging Information on the Latest Developments in Virus Removal Filtration. Tokyo: Asahi Kasei Corporation, November 1, 2000: 22-37.
68. Poulle M, Burnouf-Radosevich M, Burnouf T. Largescale preparation of highly purified human C1-inhibitor for therapeutic use. Blood Coag Fibrinolysis 1994; 5: 543-9.
69. Bunch C, Kavanagh C, Heldebrant C, Bhattacharya P, Craig WC. Alpha-1 Proteinase Inhibitor (A1PI) Virus Reduction Studies. XVII Congress of the International Society on Thrombosis and Haemostasis, Washington DC, USA, August 14-21, 1999, no. 912 (Abstracts).
70. Bunch C. Virus validation studies with the Planova® 15N filtration system and the determination of worst case conditions. Planova® Workshop USA'99. A Forum for Exchanging Information on the Latest Developments in Virus Removal Technology. Washington: Asahi Kasei Corporation, November 29, 1999: 35-57.
71. von Bonsdorff L, Tolo H, Lindeberg E, Nyman T, Harju A, Parkkinen J. Development of a pharmaceutical apotransferrin product for iron binding therapy. Biologicals 2001; 29: 27-37.
72. Abe H, Sugawara H, Hirayama J et al. Removal of parvovirus B19 from hemoglobin solution by nanofiltration. Artif Cells Blood Substit Immobil Biotechnol 2000; 28: 375-83.
73. Azari M, Boose JA, Burhop KE et al. Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin cross-linked haemoglobin (DCLHb). Biologicals 2000; 28: 81-94.
74. Tolo H, Kauppinen HL, Alm G et al. Development of a highly purified multicomponent leukocyte IFN-alpha product. J Interferon Cytokine Res 2001; 21: 913-20.
75. Brown P, Cervenakova L, McShane LM et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
76. Farrugia A. Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives. Hemophilia 2002; 8: 230-5.
77. Will RG, Kimberlin RH. Creutzfeldt-Jakob disease and the risk from blood or blood products. Vox Sang 1998; 75: 178-80.
78. Brown P. BSE and transmission through blood. Lancet 2000; 356: 955-6.
79. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
80. Brown P, Rohwer RG, Dunstan BC et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathies. Transfusion 1998; 38: 810-6.
81. Hilton DA, Ghani AC, Conyers L et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br Med J 2002; 325: 633-4.
82. Tateishi J, Sato Y, Koga M, Doi H, Ohta M. Experimental transmission of human spongiform encephalopathy to small rodents. 1. Clinical and histopathological observations. Acta Neuropathol 1980; 51: 127-34.
83. Kuroda Y, Gibbs CJ Jr, Amyx HI, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low density lymphocytes. Infect Immun 1983; 41: 154-61.
84. Hunter N, Houston F. Can prion diseases be transmitted between individuals via blood transfusion: evidence from sheep experiments. Dev Biol (Basel) 2002; 108: 93-8.
85. Tateishi J, Tashima T, I-Citamoto T. Practical method for chemical inactivation of Creutzfeldt-Jakob disease pathogen. Microbiol Immunol 1991; 35: 163-6.
86. Lee DC, Stenland CJ, Miller JL et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy during the purification of plasma proteins. Transfusion 2001; 41: 433-6.
87. MacGregor I, Drummond O, Prowse C et al. Normal prion protein is found in human plasma, but is removed by the SNBTS plasma fractionation process. Thromb Haemost 1999; 82: 86-7.
88. Foster PR, Welch AG, McLean C et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma proteins. Vox Sang 2000; 78: 86-95.
89. Brown P, Cervenakova L, McShane LM, Barber P, Rubeinstein R, Drohan W. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-78.
90. Tateishi J, Kitamoto T, Hiratani H. Creutzfeldt-Jakob pathogen in growth hormone preparations is eliminatable. Lancet 1985; 2: 1299-300.
91. Tateishi J, Kitamoto T, Ishikawa G, Manabe S. Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane 1993; 18: 357-62.
92. Tateishi J, Kitamoto T, Ishikawa G, Manabe S. Yamaguchi K. Removal of the prion protein using validatable filter (BMM). In: Beuvery EC, Griffiths JB, Zeijlemaker WP., eds. Animal Cell Technology: Development Towards the 21st Century. Netherlands: Kluwer Academic Publishers, 1995: 637-40.
93. Tateishi J, Kitamoto T, Mohri S et al. Scrapie removal using Planova® virus removal filters. Biologicals 2001; 29: 17-25.
94. Golker CF, Whiteman MD, Gugel KH et al. Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol. Biologicals 1996; 24: 103-11.
95. Blum M, Budnick MO, Chair EM, Vaz WE, MacAuley D, Rohwer RG. A bovine spongiform encephalopathy validation study for aprotinin and bovine serum albumin. Biopharm 1998; 11: 28-34.
96. Carter J, Lutz H. An overview of viral filtration in biopharmaceutical manufacturing. Eur J Parent Sci 2002; 7: 72-8.